Anzeige
Mehr »
Login
Montag, 20.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Aktienchance des Jahres! Ihre Chance auf explosive Gewinne!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
40 Leser
Artikel bewerten:
(0)

Scheid Family Wines Reports Third Quarter Fiscal 2025 Results

Finanznachrichten News

SALINAS, Calif., Jan. 20, 2025 /PRNewswire/ -- Scheid Vineyards Inc. (dba Scheid Family Wines) (OTC Markets: SVIN) announced today its financial results for the nine months ended November 30, 2024 (third quarter of fiscal 2025).

Financial Results

Total revenues decreased 17%, to $43.3 million for the nine months ended November 30, 2024, from $52.4 million in fiscal 2024. Cased goods sales decreased 6%, to $32.2 million in the first nine months of fiscal 2025, from $35.2 million in fiscal 2024, as the bottled wine business across the entire market slowed in calendar 2024. The Company's bulk wine sales decreased 22%, to $2.1 million from $2.7 million, and grape sales decreased 23%, to $1.0 million from $1.3 million. Revenues from winery processing and storage decreased 50%, to $5.2 million from $10.4 million as the result of the dissolution of a winery processing contract and a lighter than usual 2024 harvest. Gross margins decreased to 26% from 30%, primarily from a reduction in bulk wine sales prices. Industrywide, the bulk wine market continues to be over-supplied, leading to slower sales as well as reduced prices.

Sales and marketing expenses decreased 18%, to $6.8 million from $8.3 million, and general and administrative expenses decreased 6%, to $5.0 million from $5.3 million.

During the first quarter of fiscal 2025, the Company recognized revenue of $3.6 million from proceeds received from the early termination of a winery processing agreement. During the second quarter of fiscal 2025, the Company recognized a gain from the sale of non-vineyard land in the amount of $1.7 million.

Interest expense rose 146%, to $11.8 million from $4.8 million, due to increases in interest rates as each of the Company's lenders are accruing interest at the default rate of an average of 14.2%.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) increased to $8.5 million from $6.2 million, primarily from the proceeds from the early termination of a processing agreement and land sale.

In total, the Company reported a net loss of $6.8 million for the nine months ended November 30, 2024, compared to a net loss of $1.8 million for the nine months ended November 30, 2023.

2024 Harvest Update

The Company's 2024 grape harvest was completed on October 30, 2024. Overall yields were approximately 15% below the Company's five-year average yields and are generally consistent with wine grape yields from Monterey and other California coastal vineyard regions.

SCHEID VINEYARDS INC. AND SUBSIDIARY

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

NINE MONTHS ENDED NOVEMBER 30, 2024 AND 2023

(amounts in thousands, except per share data)








Nine Months Ended November 30,





2024


2023


REVENUES:







Cased goods sales



$

32,177


$

35,228


Bulk wine sales



2,085


2,696


Winery processing and storage revenues



5,190


10,362


Grape sales



1,030


1,321


Direct sales revenues



2,350


2,286


Vineyard management revenues



467


536


Other revenues



9


10


Total revenues



43,308


52,439


COST OF SALES



(31,877)


(36,578)


GROSS PROFIT



11,431


15,861


Sales and marketing expenses



(6,790)


(8,348)


General and administrative expenses



(4,970)


(5,258)


OPERATING (LOSS) INCOME



(329)


2,255


Interest expense, net



(11,783)


(4.787)


Proceeds from termination of processing agreement



3,613


-


Gain on sale of property, plant and equipment



1,715


80


Other income (loss)



9


(40)


LOSS BEFORE BENEFIT FROM INCOME TAXES



(6,775)


(2,492)


BENEFIT FROM INCOME TAXES



-


713


NET LOSS



$

(6,775)


$

(1,779)


















NET LOSS PER SHARE



$

(7.39)


$

(1.94)









WEIGHTED AVERAGE SHARES OUTSTANDING



917


915


About Scheid Family Wines

Scheid Family Wines, a family-owned and operated wine company for over 50 years, is ranked among the top 25 largest wine producers in the United States. Based in Monterey County, California, Scheid is vertically integrated to bring high quality estate grown wines to the marketplace from its sustainably and organically certified vineyards and grower partners throughout the Central Coast. Scheid's innovative, luxury-level winery is 100% powered by renewable wind energy generated by a 400-foot-tall wind turbine, which also supplies energy to the local community. The Scheid Family Wines globally distributed brand portfolio includes Scheid Vineyards, Sunny with a Chance of Flowers, VDR (Very Dark Red), Grandeur (organically certified), Fog & Light, Metz Road, District 7, Ryder Estate, and HOXIE, a premium wine spritzer. Scheid Family Wines sells internationally to over 30 countries and is one of the largest producers of premium exclusive brands.

Please visit www.scheidfamilywines.com and www.otcmarkets.com/stock/SVIN/quote for more information.

CONTACT:

Scott Scheid, President and CEO, [email protected]


Mike Thomsen, Chief Financial Officer, [email protected]

SOURCE Scheid Family Wines

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.